BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting
(NASDAQ: BTAI) Delayed: 1.26 -0.04 (3.08%)
Previous Close $1.30    52 Week High $ 
Open $1.28    52 Week Low $ 
Day High $1.33    P/E N/A 
Day Low $1.25    EPS $ 
Volume 724,073       

(NASDAQ: BTAI) Delayed: 1.26 -0.04 (3.08%)
Previous Close $1.30    52 Week High $ 
Open $1.28    52 Week Low $ 
Day High $1.33    P/E N/A 
Day Low $1.25    EPS $ 
Volume 724,073